JP2016156013A - Pharmaceutical packaging film - Google Patents

Abstract

Disclosed is a drug packaging film which can realize excellent chemical resistance and water solubility and has high visibility.
A drug packaging film containing polyvinyl alcohol, wherein the drug packaging film has an orientation of 10 to 150 nm, and the polyvinyl alcohol has a saponification degree of 90.0 to 99.0. Drug packaging film that is mol%.
[Selection figure] None

Description

The present invention relates to a film for drug packaging which can realize excellent chemical resistance and water solubility and has high visibility.

Polyvinyl alcohol (hereinafter also referred to as PVA) is widely used as a packaging material because it is excellent in transparency, oil resistance, chemical resistance, and gas barrier properties such as oxygen. In recent years, it has been widely used as a packaging material for foods, pharmaceuticals, industrial chemicals, agricultural chemicals and the like in which deterioration due to oxidation has a great influence on properties.

When using a film made of PVA for packaging applications such as medicine, for example, a method of making a bag after filling the medicine while continuously feeding out the PVA film is used.
However, when an acidic or alkaline substance is packaged using such a PVA film, the content (acidic or alkaline substance) reacts with polyvinyl alcohol during the storage period, and the water-soluble film becomes insoluble. There was a problem.
In addition, a new problem has arisen that the drop strength is reduced during the storage period.

In contrast, Patent Document 1 improves the water solubility after receiving a heat history by adding a polybasic acid or an alkali metal salt thereof and a hydrazine compound to a polyvinyl alcohol resin. The technology is described.
However, the method of Patent Document 1 has the problem that the flexibility of the film is low and the processing suitability when packaging the drug is poor, and the water solubility is still insufficient, and the dissolution time is particularly long. It was.
On the other hand, in a water-soluble film used for packaging applications such as agricultural chemicals and drugs, the performance as a water-soluble film can be improved by modifying PVA with a carboxyl group or adding a plasticizer. However, there has been a new problem that the film gradually turns pale yellow due to contact with the medicine to be filled.

On the other hand, Patent Document 2 discloses a water-soluble film in which a plasticizer and a sulfite are added to a polyvinyl alcohol-based resin. It is said that a water-soluble film with little coloring is obtained.
However, there is a problem that the dissolution time cannot be shortened even if sulfite is added to the water-soluble film. In addition, sulfite reacts with a weak acid to generate sulfur dioxide gas, and there is also a problem that a bad odor is generated from the water-soluble film.

JP 2003-171521 A JP 2005-179390 A

An object of the present invention is to provide a film for drug packaging which can realize excellent chemical resistance and water solubility and has high visibility.

The present invention is a drug packaging film containing polyvinyl alcohol, wherein the drug packaging film has an orientation of 10 to 150 nm, and the polyvinyl alcohol has a saponification degree of 90.0 to 99.0. It is a film for drug packaging which is mol%.
The present invention is described in detail below.

The present inventor uses polyvinyl alcohol having a predetermined degree of saponification as a component of a film for drug packaging, and makes the orientation of the film for drug packaging within a predetermined range, thereby providing excellent chemical resistance and water solubility. It has been found that a film for drug packaging having high visibility can be realized. Furthermore, it has been found that such a medicine packaging film can maintain excellent visibility even after medicine packaging, and the present invention has been completed.
Hereinafter, the detail of each component used for the film for medicine packaging of this invention is demonstrated.

(Polyvinyl alcohol (PVA))
The film for drug packaging of the present invention contains polyvinyl alcohol.
The said polyvinyl alcohol becomes a main structural component of the film for medicine packaging of this invention.

The polyvinyl alcohol can be obtained by polymerizing a vinyl ester to obtain a polymer according to a conventionally known method, and then saponifying the polymer, that is, hydrolyzing. In general, alkali or acid is used for saponification. It is preferable to use an alkali for the saponification. As said polyvinyl alcohol, only 1 type may be used and 2 or more types may be used together.

Examples of the vinyl ester include vinyl acetate, vinyl formate, vinyl propionate, vinyl butyrate, vinyl pivalate, vinyl versatate, vinyl laurate, vinyl stearate and vinyl benzoate.

The method for polymerizing the vinyl ester is not particularly limited. Examples of the polymerization method include a solution polymerization method, a bulk polymerization method, and a suspension polymerization method.

Examples of the polymerization catalyst used when polymerizing the vinyl ester include 2-ethylhexyl peroxydicarbonate (“TrigonoxEHP” manufactured by Tianjin McEIT), 2,2′-azobisisobutyronitrile (AIBN), t-butyl. Peroxyneodecanoate, bis (4-t-butylcyclohexyl) peroxydicarbonate, di-n-propylperoxydicarbonate, di-n-butylperoxydicarbonate, di-cetylperoxydicarbonate and di-s-butylperoxy Examples include dicarbonate. As for the said polymerization catalyst, only 1 type may be used and 2 or more types may be used together.

Since the saponification degree can be easily controlled within a suitable range, the polymer obtained by polymerizing the vinyl ester is preferably a polyvinyl ester. The polymer obtained by polymerizing the vinyl ester may be a copolymer of the vinyl ester and another monomer. That is, the polyvinyl alcohol may be formed using a copolymer of vinyl ester and another monomer. Examples of the other monomers, that is, comonomers to be copolymerized, include olefins, (meth) acrylic acid and salts thereof, (meth) acrylic acid esters, (meth) acrylamide derivatives, N-vinylamides, vinyl ethers, and nitriles. , Vinyl halides, allyl compounds, maleic acid and salts thereof, maleic acid esters, itaconic acid and salts thereof, itaconic acid esters, vinylsilyl compounds, and isopropenyl acetate. As for the other monomer, only one kind may be used, or two or more kinds may be used in combination.

Examples of the olefins include ethylene, propylene, 1-butene and isobutene. Examples of the (meth) acrylic acid esters include methyl (meth) acrylate, ethyl (meth) acrylate, n-propyl (meth) acrylate, i-propyl (meth) acrylate, and (meth) acrylic acid n-. Examples include butyl and 2-ethylhexyl (meth) acrylate. Examples of the (meth) acrylamide derivative include acrylamide, n-methylacrylamide, N-ethylacrylamide, N, N-dimethylacrylamide, and (meth) acrylamidepropanesulfonic acid and salts thereof. Examples of the N-vinyl amides include N-vinyl pyrrolidone. Examples of the vinyl ethers include methyl vinyl ether, ethyl vinyl ether, n-propyl vinyl ether, i-propyl vinyl ether, and n-butyl vinyl ether. Examples of the nitriles include (meth) acrylonitrile. Examples of the vinyl halides include vinyl chloride and vinylidene chloride. Examples of the allyl compound include allyl acetate and allyl chloride. Examples of the vinylsilyl compound include vinyltrimethoxysilane.

The PVA has a saponification degree of 90.0 to 99.0 mol%.
When the saponification degree is not less than the above lower limit and not more than the above upper limit, it becomes easy to control the water resistance of the film for drug packaging and the dissolution time when the drug is opened, and both the water resistance and the control of the dissolution time are controlled. The balance can be improved.
The preferable lower limit of the saponification degree of the PVA is 92.0 mol%, and the preferable upper limit is 98.0 mol%.

The saponification degree is measured according to JIS K6726. The saponification degree indicates the proportion of units that are actually saponified to vinyl alcohol units among the units converted to vinyl alcohol units by saponification.
The method for adjusting the saponification degree is not particularly limited. The saponification degree can be appropriately adjusted according to saponification conditions, that is, hydrolysis conditions.

The modified PVA preferably has a saponification degree distribution standard deviation (σ) of 0.1 to 1.0 mol%.
When the saponification degree distribution standard deviation is not less than the above lower limit and not more than the above upper limit, the solubility and chemical resistance of the film for drug packaging are improved, the dissolution time when the drug is released, and storage when the drug is packaged Both periods can be improved in a balanced manner.
A more preferable lower limit of the standard deviation of saponification degree distribution of the modified PVA is 0.2 mol%, and a more preferable upper limit is 0.9 mol%.
The standard deviation of the saponification degree distribution is an index indicating the saponification degree variation in the modified PVA, and can be measured and calculated using, for example, FT-IR.

The degree of polymerization of the PVA is not particularly limited. The preferable lower limit of the polymerization degree of the PVA is 400, the more preferable lower limit is 500, the still more preferable lower limit is 600, the particularly preferable lower limit is 900, the preferable upper limit is 2000, the more preferable upper limit is 1800, and the further preferable upper limit is 1500. When the degree of polymerization is not less than the above lower limit and not more than the above upper limit, the viscosity of the aqueous solution becomes appropriate when a film for drug packaging is formed. When the degree of polymerization is not more than the above upper limit, the strength of the PVA film for drug packaging is further increased and water resistance is obtained. The degree of polymerization is measured according to JIS K6726.

The PVA has a preferred lower limit of viscosity of 3 mPa · s and a preferred upper limit of 30 mPa · s measured at 20 ° C. as a 4 wt% aqueous solution. When the viscosity is less than 3 mPa · s, water resistance may be impaired. When the viscosity exceeds 30 mPa · s, the dissolution time may be long. A more preferable lower limit of the viscosity is 8 mPa · s, and a more preferable upper limit is 20 mPa · s.
The viscosity can be measured according to JIS K6726.

Modified PVA may be used as the PVA.
The modified PVA is preferably modified with at least one hydrophilic group selected from the group consisting of a sulfonic acid group, a pyrrolidone ring, an amino group, and a carboxyl group.
Of these, a sulfonic acid group and a pyrrolidone ring group are preferable. The hydrophilic group includes salts such as sodium and potassium in addition to the functional group described above.
The modified PVA modified with the hydrophilic group is obtained by copolymerizing unmodified polyvinyl alcohol and another monomer having the hydrophilic group, or adding a hydrophilic group to the unmodified polyvinyl alcohol. What is obtained by doing is included.

Examples of the modified PVA include sulfonic acid group-modified polyvinyl alcohol, pyrrolidone ring-modified polyvinyl alcohol, amino group-modified polyvinyl alcohol, and carboxyl group-modified polyvinyl alcohol.

The sulfonic acid group-modified polyvinyl alcohol is not particularly limited as long as the sulfonic acid group is introduced by modification, but the sulfonic acid group is bonded to the polymer main chain via a linking group. preferable.
Examples of the linking group include an amide group, an alkylene group, an ester group, and an ether group. Of these, a combination of an amide group and an alkylene group is preferable.
The sulfonic acid group is preferably a sulfonate salt, and particularly preferably a sodium sulfonate group.
In particular, when the modified PVA is sodium sulfonate-modified polyvinyl alcohol, the sodium sulfonate-modified polyvinyl alcohol preferably has a structural unit represented by the following formula (1).

In the above formula (1), ^{R 1} represents an alkylene group having 1 to 4 carbon atoms.

When the modified PVA is pyrrolidone ring-modified polyvinyl alcohol, the pyrrolidone ring-modified polyvinyl alcohol preferably has a structural unit represented by the following formula (2).

When the modified PVA is amino group-modified polyvinyl alcohol, the amino group-modified polyvinyl alcohol preferably has a structural unit represented by the following formula (3).

In the above formula (3), ^{R 2} represents a single bond or an alkylene group having 1 to 10 carbon atoms.

When the modified PVA is a carboxyl group-modified polyvinyl alcohol, the carboxyl group-modified polyvinyl alcohol has a structural unit represented by the following formula (4-1), (4-2) or (4-3). Is preferred.

In the above formulas (4-1), (4-2) and (4-3), X ¹ , X ² , X ³ , X ⁴ and X ⁵ are each independently a hydrogen atom, a metal atom or a methyl group. Represent. That is, in this specification, the carboxyl group contained in the structural unit having a carboxyl group includes a salt of the carboxyl group and a methyl ester. As a metal atom, a sodium atom etc. are mentioned, for example.
In the formula (4-2), ^{R 3} represents an alkylene group having 1 to 10 carbon atoms.

Examples of commercially available modified PVA include “KL-318”, “KL-118”, “KM-618”, and “KM-118” (all manufactured by Kuraray Co., Ltd.).

The content of the structural unit having a hydrophilic group in the modified PVA is preferably 0.2 to 10 mol%. When the content of the structural unit having a hydrophilic group is not less than the above lower limit and not more than the above upper limit, the film may be discolored or broken over a long period of time against chlorine-containing sanitary agents or oxidizing chemicals. A film with no resistance can be obtained.
The minimum with more preferable content of the structural unit which has the said hydrophilic group is 0.5 mol%, and a more preferable upper limit is 8 mol%.

Examples of the method for producing the modified PVA include a method of copolymerizing unmodified polyvinyl alcohol and another monomer having the hydrophilic group, a method of adding a hydrophilic group to unmodified polyvinyl alcohol, and the like.

In 100% by weight of the drug packaging film of the present invention, the preferred lower limit of the content of the polyvinyl alcohol is 70% by weight, and the preferred upper limit is 97% by weight.
When the content of the polyvinyl alcohol is equal to or more than the lower limit, a drug packaging film having better quality without bleeding out of the plasticizer from the drug packaging film may be obtained. When the content of the polyvinyl alcohol is not more than the above upper limit, the strength of the PVA film for drug packaging is further increased, and water resistance may be obtained.

The film for drug packaging of the present invention contains a plasticizer.
A film for drug packaging is required to have high tensile strength and durability because it can be transported, stored and used even in hot and humid areas and cold regions. Particularly, impact resistance at low temperatures is important. By containing a plasticizer, the film for drug packaging of the present invention can lower the glass transition point, and can improve durability at low temperatures. Moreover, the solubility with respect to the water of the film for medicine packaging can also be improved by containing the said plasticizer.

The plasticizer is not particularly limited as long as it is generally used as a plasticizer for PVA, and examples thereof include glycerin, diglycerin, diethylene glycol, trimethylolpropane, triethylene glycol, dipropylene glycol, and propylene glycol. Polyethylenes such as polyhydric alcohols, polyethylene glycols, polypropylene glycols, phenol derivatives such as bisphenol A and bisphenol S, amide compounds such as N-methylpyrrolidone, polyhydric alcohols such as glycerin, pentaerythritol, sorbitol and ethylene oxide Examples include added compounds and water. These may be used alone or in combination of two or more.
Among the above plasticizers, glycerin, trimethylolpropane, polyethylene glycol, polypropylene glycol, triethylene glycol, dipropylene glycol, and propylene glycol are preferable because water solubility can be improved, and the effect of improving water solubility is particularly large. Therefore, glycerin and trimethylolpropane are particularly preferable.

In the drug packaging film of the present invention, the preferred lower limit of the plasticizer content relative to 100 parts by weight of polyvinyl alcohol is 3 parts by weight, and the preferred upper limit is 15 parts by weight. When the content of the plasticizer is less than 3 parts by weight, the plasticizer blending effect may not be obtained. On the other hand, when the blending ratio of the plasticizer exceeds 15 parts by weight, the bleeding out of the plasticizer increases, and the resulting anti-blocking property of the film for drug packaging may deteriorate.
The minimum with said more preferable plasticizer content is 3.2 weight part, and a more preferable upper limit is 13 weight part.

The film for drug packaging of the present invention has an orientation of 10 to 150 nm.
When the orientation is not less than the above lower limit and not more than the above upper limit, the solubility and chemical resistance of the film for drug packaging are improved, and both the dissolution time when the drug is released and the storage period when the drug is packaged The balance can be improved.
The preferable lower limit of the orientation is 15 nm, and the preferable upper limit is 120 nm.
The orientation is an index indicating the regularity of the PVA molecular arrangement in the drug packaging film, and can be measured, for example, by using a phase difference measuring device (KOBRA-WR, manufactured by Oji Scientific Instruments).

The thickness of the film for drug packaging of the present invention is preferably 100 μm, more preferably 80 μm, and still more preferably 75 μm. The preferable lower limit of the thickness of the film for drug packaging of the present invention is 10 μm. When the thickness of the drug packaging film is not less than the above lower limit, the strength of the film for packaging the drug is further increased. When the thickness of the drug packaging film is not more than the above upper limit, the packaging property and heat sealability as the drug packaging film are further improved, the processing time is further shortened, and the productivity is further increased. .

The drug packaging film of the present invention may further contain, as necessary, usual additives such as a colorant, a fragrance, an extender, an antifoaming agent, a release agent, an ultraviolet absorber, and a surfactant. Absent. In particular, in order to improve the releasability between the metal surface such as a die or drum of the film forming apparatus and the formed film or film stock solution, the ratio of 0.01 to 5 parts by weight of the surfactant with respect to 100 parts by weight of PVA It is preferable to mix with.

The film for drug packaging of the present invention has a lower limit of contact angle of 20 ° and an upper limit of 50 ° measured using distilled water by a droplet method. When the contact angle is 20 ° or more, it is possible to obtain a film for drug packaging excellent in feeding property. When the contact angle is 50 ° or less, a film for drug packaging in which roll contamination is suppressed can be obtained. The preferable lower limit of the contact angle is 23 °, the more preferable lower limit is 30 °, the preferable upper limit is 49 °, and the more preferable upper limit is 40 °.
The contact angle can be measured according to JIS R 3257. For example, using a contact angle meter Thelite (manufactured by Biolin Scientific), it can be measured by dropping distilled water onto a film for drug packaging.

(Method for producing film for drug packaging)
Although it does not specifically limit as a manufacturing method of the film for medicine packaging of this invention, The method etc. which cast and dry the PVA aqueous solution containing PVA, a plasticizer, and water on a support member can be used. Specific examples include a solution casting method (casting method), a roll coating method, a spin coating method, a screen coating method, a fountain coating method, a dipping method, and a spray method.

The PVA aqueous solution contains water together with the PVA and the plasticizer. The PVA is mainly dissolved in the water.

In the PVA aqueous solution, the content of the water is 300 parts by weight or more, preferably 400 parts by weight or more, more preferably 500 parts by weight or more with respect to 100 parts by weight of components other than water containing the PVA.
The water content is 900 parts by weight or less, preferably 800 parts by weight or less, more preferably 700 parts by weight or less. When the water content is not less than the above lower limit, the viscosity of the PVA aqueous solution becomes moderately low, and the casting of the PVA aqueous solution becomes easy. When the water content is not more than the above upper limit, the viscosity of the PVA aqueous solution becomes moderately high, the casting of the PVA aqueous solution becomes easy, the drying time is further shortened, and the orientation of the film for drug packaging is further increased. An enhanced and even better quality drug packaging film is obtained.

The support member is preferably capable of supporting the PVA film obtained by maintaining the PVA aqueous solution on the surface and casting the PVA aqueous solution. Examples of the material for the support member include polyolefin, polyester, acrylic resin, and the like. You may use the supporting member formed with materials other than these. Examples of the polyolefin include ethylene, polypropylene, ethylene-vinyl acetate copolymer, and ethylene-vinyl alcohol copolymer. Examples of the polyester include polyethylene terephthalate and polyethylene naphthalate. The material of the support member is preferably not PVA.

The drying method after casting the PVA aqueous solution on the support member can be any suitable method and is not particularly limited. Examples of the drying method include a method of natural drying and a method of heat drying at a temperature lower than the glass transition temperature of the modified PVA.

When producing the film for drug packaging of the present invention, it is preferable to perform the stretching step during the drying or after the drying. By performing such a process, the orientation of the film for drug packaging can be more preferably within a predetermined range.
Examples of the stretching step include stretching using a roll, stretching using a tenter, stretching using a winding device, stretching using drying shrinkage, and stretching combining these.
Moreover, as a draw ratio in the said extending process, 1.05-3 times are preferable. Moreover, 1.1 to 2.8 times is more preferable.

ADVANTAGE OF THE INVENTION According to this invention, while being able to implement | achieve the outstanding chemical resistance and water solubility, the film for chemical | medical agent packaging which has high visibility can be provided.
Furthermore, it is possible to provide a drug packaging film capable of maintaining high visibility even after a long period of time after packaging the drug.

Examples of the present invention will be described in more detail with reference to the following examples, but the present invention is not limited to these examples.

Example 1
94 parts by weight of unmodified polyvinyl alcohol (average polymerization degree 1300, saponification degree 98.0 mol%), 3 parts by weight of glycerin (manufactured by Wako Pure Chemical Industries) as a plasticizer, trimethylolpropane (manufactured by Wako Pure Chemical Industries, Ltd.) 3) Part by weight was dissolved in 600 parts by weight of water to prepare a 16.7% by weight aqueous solution.
The obtained PVA aqueous solution was applied onto a polyethylene terephthalate (PET) film (thickness 50 μm) as a support member using an auto film applicator (“PI-1210” manufactured by Tester Sangyo Co., Ltd.) and dried at 80 ° C. for 5 minutes. And then dried at 100 ° C. for 20 minutes to obtain a PVA film (thickness 50 μm) on the support member.
The support was peeled from the obtained PVA film to obtain a film for drug packaging, and then exposed to an environment of a temperature of 23 ° C. and a relative humidity of 50% RH for 24 hours.
Thereafter, the film for drug packaging was cut into a size of 150 mm × 50 mm and set in a tensile tester so that the width was 100 mm. Thereafter, the film was stretched until the width became 150 mm (stretching ratio: 1.5 times) to obtain a film for drug packaging.

(Example 2)
A drug packaging film was obtained in the same manner as in Example 1 except that the film was stretched until the width reached 200 mm (stretching ratio: 2.0 times).

(Example 3)
A drug packaging film was obtained in the same manner as in Example 1 except that the film was stretched until the width reached 250 mm (stretching ratio: 2.5 times).

Example 4
Instead of unmodified polyvinyl alcohol, sodium sulfonate-modified polyvinyl alcohol having the structure shown in formula (1) (average polymerization degree 600, R ¹ = CH ₂ , saponification degree 90.2 mol%, sodium sulfonate modification amount 4 A drug packaging film was obtained in the same manner as in Example 1 except that (mol%) was used.

(Example 5)
Implemented except that pyrrolidone ring-modified polyvinyl alcohol (average polymerization degree 1000, saponification degree 90.5 mol%, pyrrolidone modification amount 4 mol%) having the structure shown in formula (2) was used in place of unmodified polyvinyl alcohol. In the same manner as in Example 1, a drug packaging film was obtained.

(Example 6)
Instead of unmodified polyvinyl alcohol, amino group-modified polyvinyl alcohol having the structure shown in formula (3) (average polymerization degree 600, R ² = CH ₂ , saponification degree 90.0 mol%, amino group modification amount 8 mol% ) Was used in the same manner as in Example 1 to obtain a drug packaging film.

(Example 7)
Instead of unmodified polyvinyl alcohol, carboxyl group-modified polyvinyl alcohol having a structure represented by formula (4-2) (average polymerization degree 700, R ³ = CH ₂ , saponification degree 91.2 mol%, carboxyl group modification amount 1 0.5 mol%) was used in the same manner as in Example 1 to obtain a drug packaging film.

(Example 8)
Instead of 94 parts by weight of unmodified polyvinyl alcohol, sodium sulfonate-modified polyvinyl alcohol having the structure shown in formula (1) (average polymerization degree 1200, R ¹ = CH ₂ , saponification degree 95.4 mol%, sodium sulfonate A drug packaging film was obtained in the same manner as in Example 1 except that 5 parts by weight of the modified amount 4 mol%) and 89 parts by weight of unmodified polyvinyl alcohol (average degree of polymerization 1300, degree of saponification 90.0 mol%) were used. It was.

Example 9
A drug packaging film was obtained in the same manner as in Example 4 except that the film was stretched until the width reached 250 mm (stretching ratio: 2.5 times).

(Example 10)
A drug packaging film was obtained in the same manner as in Example 5 except that the film was stretched until the width reached 250 mm (stretching ratio: 2.5 times).

(Example 11)
A drug packaging film was obtained in the same manner as in Example 6 except that the film was stretched until the width reached 250 mm (stretching ratio: 2.5 times).

(Example 12)
A drug packaging film was obtained in the same manner as in Example 7 except that the film was stretched until the width reached 250 mm (stretching ratio: 2.5 times).

(Comparative Example 1)
A drug packaging film was obtained in the same manner as in Example 1 except that the stretching step was not performed.

(Comparative Example 2)
A drug packaging film was obtained in the same manner as in Example 1 except that the film was stretched until the width reached 300 mm (stretching ratio: 3.0 times).

(Comparative Examples 3-6)
A drug packaging film was obtained in the same manner as in Examples 4 to 7 except that the film was not stretched.

(Comparative Example 7)
A drug packaging film was obtained in the same manner as in Example 4 except that the film was stretched until the width reached 300 mm (stretching ratio: 3.0 times).

(Comparative Example 8)
A drug packaging film was obtained in the same manner as in Example 5 except that the film was stretched to a width of 300 mm (stretching ratio: 3.0 times).

(Comparative Example 9)
A drug packaging film was obtained in the same manner as in Example 6 except that the film was stretched until the width reached 300 mm (stretching ratio: 3.0 times).

(Comparative Example 10)
A drug packaging film was obtained in the same manner as in Example 7 except that the film was stretched until the width reached 300 mm (stretching ratio: 3.0 times).

(Comparative Example 11)
Example 1 except that unmodified polyvinyl alcohol (polymerization degree 1300, saponification degree 80.4 mol%) was used instead of unmodified polyvinyl alcohol (average polymerization degree 1300, saponification degree 98.0 mol%). Similarly, a drug packaging film was obtained.

(Evaluation)
The following evaluation was performed about the film obtained by the Example and the comparative example. The results are shown in Table 1.
In addition, when using the mixture of polyvinyl alcohol, the average degree of polymerization of Table 1, the degree of saponification, and the amount of modification | denaturation group described the numerical value which totaled what divided each numerical value with the addition ratio.

(1) Orientation The obtained drug packaging film was exposed to an environment of a temperature of 23 ° C. and a relative humidity of 50% RH for 24 hours. Thereafter, the film for drug packaging was measured with a phase difference measuring device (KOBRA-WR, manufactured by Oji Scientific Instruments) at an incident angle of 45 °, and the measured value of the phase difference R was defined as an orientation value.

(2) Water solubility (dissolution time)
After obtaining a film for drug packaging, the film was exposed to an environment of a temperature of 23 ° C. and a relative humidity of 50% RH for 24 hours. Then, cut the drug packaging film into a size of 35 mm x 40 mm and fix it on a jig. Put water (500 ml) into a 500 ml beaker and stir with a stirrer (the bottom of the spiral reaches the 400 ml mark) Was kept at 23 ° C., and the film fixed on the jig was immersed in the water. The time when the film residue was not visible from the jig was measured and evaluated according to the following criteria.
○○: Less than 20 seconds ○: More than 20 seconds but less than 30 seconds ×: More than 30 seconds

(3) Chemical resistance A 5 cm × 4 cm bag was prepared from the obtained film for drug packaging, and 20 g of sodium trichloroisocyanurate was actually packaged in the bag, further sealed in an aluminum bag, and then sealed at a temperature of 40 ° C. and a humidity of 70 It was left in a constant temperature and humidity oven of% RH for 1 month. Thereafter, the appearance of the film for drug packaging was visually observed.
○: No change in appearance ×: The appearance is colored yellow or brown

(4) Visibility About the obtained film | membrane for drug packaging, the haze in 20 degreeC was measured using the haze meter (The Tokyo Denshoku Co., Ltd. make, TC-H3DPK), and the following references | standards evaluated.
○: Haze is less than 3.5% ×: Haze is 3.5% or more

(5) Endurance visibility A 5 cm × 4 cm bag is prepared from the obtained film for packaging medicine, and 20 g of sodium trichloroisocyanurate is actually packaged in the bag, further sealed in an aluminum bag, and then sealed at a temperature of 40 ° C. and a humidity of 70. It was left in a constant temperature and humidity oven of% RH for 1 month. Then, the film part was cut out, the haze at 20 degreeC was measured using the haze meter (The Tokyo Denshoku Co., Ltd. make, TC-H3DPK), and the following references | standards evaluated. Further, the haze change rate was calculated from the difference from the haze measured in “(4) Visibility”.
○: Haze is less than 3.5% and haze change rate is less than 20% ×: Haze is 3.5% or more, or haze change rate is 20% or more

ADVANTAGE OF THE INVENTION According to this invention, while being able to implement | achieve the outstanding chemical resistance and water solubility, the film for chemical | medical agent packaging which has high visibility can be provided.

Claims (3)

A drug packaging film containing polyvinyl alcohol,
The orientation of the film for drug packaging is 10 to 150 nm, and
The polyvinyl alcohol has a saponification degree of 90.0 to 99.0 mol%. The drug according to claim 1, wherein the polyvinyl alcohol is a modified polyvinyl alcohol modified with at least one hydrophilic group selected from the group consisting of a sulfonic acid group, a pyrrolidone ring, an amino group and a carboxyl group. Packaging film. The film for drug packaging according to claim 2, wherein the content of the structural unit having a hydrophilic group in the modified polyvinyl alcohol is 0.2 to 10 mol%.